Vanguard Capital Management’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$40.7M Sell
1,626,585
-64,986
-4% -$1.65M ﹤0.01% 2012
2026
Q2
$42.9M Sell
1,691,571
-92,478
-5% -$2.19M ﹤0.01% 2030
2026
Q1
$40.3M Buy
+1,784,049
New +$39.6M ﹤0.01% 1973

Other funds holding PCRX

Vanguard Capital Management's PCRX Position: Q3 2026 in Review

Vanguard Capital Management reduced its Pacira BioSciences (PCRX) stake by 3.8% in Q3 2026, selling an estimated $1.65M and leaving 1,626,585 shares worth $40.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2012.

Vanguard Capital Management first reported a position in PCRX in Q1 2026 and has held it in 3 quarters since. The position peaked at $42.9M in Q2 2026. 258 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

  • Vanguard Capital Management held 1,626,585 shares of Pacira BioSciences worth $40.7M as of Q3 2026.
  • Vanguard Capital Management sold 64,986 Pacira BioSciences shares in Q3 2026, an estimated $1.65M.
  • Pacira BioSciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2012 holding.
  • Vanguard Capital Management first reported a position in Pacira BioSciences in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Pacira BioSciences position peaked at $42.9M in Q2 2026.
  • 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.